Laurus Labs Limited
LAURUSLABS
Rang in Aktien
#1736
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Aktienkurs
$22.83
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$12.34B
Veränderung (1 Tag)
0.51%
Veränderung (1 Jahr)
117.95%
Land
IN
Handel Laurus Labs Limited (LAURUSLABS)
Kategorie
Healthcare
Gewinn für Laurus Labs Limited (LAURUSLABS)
Gewinn im Jun 2026 TTM: $158.77M
Laut den aktuellen Finanzberichten von Laurus Labs Limited betragen die aktuellen Gewinne des Unternehmens $158.77M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $27.63M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $134.55M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Laurus Labs Limited von 2013 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $158.77M | 178.14% |
| 2025 | $57.08M | 106.57% |
| 2024 | $27.63M | -79.46% |
| 2023 | $134.55M | -5.75% |
| 2022 | $142.76M | -19.68% |
| 2021 | $177.74M | 356.04% |
| 2020 | $38.97M | 126.00% |
| 2019 | $17.25M | -52.71% |
| 2018 | $36.46M | 0.99% |
| 2017 | $36.11M | 41.84% |
| 2016 | $25.45M | 137.71% |
| 2015 | $10.71M | -3.94% |
| 2014 | $11.15M | -29.65% |
| 2013 | $15.85M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,011.36% |
IN
|
